Genmab A/S Stock

Genmab A/S FCF Growth

The Year-over-Year Free Cash Flow Growth of Genmab A/S (GMAB.CO) as of Aug 19, 2026 is 4.43 %. In the previous year, Year-over-Year Free Cash Flow Growth was 6.53 % — a change of -32.09% (lower).

FCF Growth

4.43 %

YoY

-32.09%

Last updated:

Year-over-Year Free Cash Flow Growth of Genmab A/S is 2026 4.43 % . Year-over-Year Free Cash Flow Growth of Genmab A/S was 2025 6.53 % . It decreases by -32.09% lower compared to the previous year.
Access this data via the Eulerpool API

Genmab A/S Stock analysis

What does Genmab A/S do? Genmab A/S is a Danish biotechnology company specializing in the discovery and development of antibody therapies for cancer and other serious diseases. The company was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab A/S stock

Year-over-Year Free Cash Flow Growth of Genmab A/S is 4.43 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Genmab A/S since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Genmab A/S historically and in real time.

Access this data via the Eulerpool API

Growth — Genmab A/S

All Key Metrics — Genmab A/S